Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045305 · ClinicalTrials.gov registry record · Phase 2
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00045305 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 17 participants.
The verdict
NCT00045305, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before transplant and cyclosporine or mycophenolate mofetil after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving pentostatin together with photopheresis and total-body irradiation work before donor bone marrow transplant in treating patients with myelodysplastic syndromes.
Interventions
- DRUG Methotrexate
- DRUG Cyclosporine
- DRUG Mycofenolate mofetil
- DRUG Pentostatin
- DRUG Photopheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-10-24 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045305
The ClinicalTrials.gov registry entry for NCT00045305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Methotrexate is the first listed.
NCT00045305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045305 about?
NCT00045305 is a clinical study titled "Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes". RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the...
What is the current status of trial NCT00045305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2006-10-24. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00045305?
The interventions under investigation include: Methotrexate (DRUG), Cyclosporine (DRUG), Mycofenolate mofetil (DRUG), Pentostatin (DRUG), Photopheresis (DRUG).
Who is sponsoring clinical trial NCT00045305?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.